INmune Bio Updates Shareholders on Clinical Progress for CORDStrom™ and XPro™, Extends Cash Runway
INMB sits 30% above its 52-week low of $1.38.
Summary
Inmune Bio issued a shareholder letter detailing significant clinical progress for its CORDStrom™ and XPro™ programs, including upcoming regulatory submissions and refined trial strategies, alongside an extended cash runway through 2026.
Key Events · Product Development and Regulatory · INMB
-
CORDStrom™ Program Advances Towards Regulatory Filings
The company is preparing a Marketing Authorization Application (MAA) for CORDStrom™ in the UK by mid-2026, followed by a Biologics License Application (BLA) in the U.S. by late 2026 for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
-
XPro™ Alzheimer's Trial Shows Promise in Subpopulation
Despite the broader Phase 2 MINDFuL trial not meeting its primary endpoint, XPro™ demonstrated meaningful cognitive and biomarker signals in a predefined subpopulation of early Alzheimer's patients with neuroinflammation, informing future development.
-
Extended Financial Runway
Inmune Bio reported $27.7 million in cash and cash equivalents as of September 30, 2025, providing sufficient funds to support operations through year-end 2026.
Analysis · INMB · Life Sciences
Inmune Bio provided a comprehensive shareholder update detailing significant progress across its key clinical programs and financial position. The CORDStrom™ program for RDEB is advancing towards Marketing Authorization Application (MAA) in the UK by mid-2026 and a Biologics License Application (BLA) in the U.S. by late 2026, marking critical regulatory milestones. For the XPro™ Alzheimer's disease trial, while the broader Phase 2 MINDFuL study did not meet its primary endpoint, the company identified meaningful signals in a predefined subpopulation of early AD patients with neuroinflammation, providing a refined path forward for registrational trials. The company also reported a strong cash position of $27.7 million as of September 30, 2025, which is expected to fund operations through year-end 2026, providing crucial financial stability for a clinical-stage biotech.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INMB was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.9M. The 52-week trading range was $1.38 to $11.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.